Basilea Pharmaceutica BSLN

SWX: BSLN | ISIN: CH0011432447   13/11/2024
41,00 CHF (-0,49%)
(-0,49%)   13/11/2024

10 oktober 2024 · Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year · Persbericht

24 september 2024 · Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis · Persbericht

19 september 2024 · Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding · Persbericht

6 september 2024 · Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea · Persbericht

27 augustus 2024 · European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea · Persbericht

21 augustus 2024 · Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea · Persbericht

13 augustus 2024 · Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance · Persbericht

20 juni 2024 · Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation · Persbericht

16 mei 2024 · Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea · Persbericht

3 mei 2024 · Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024 · Persbericht

24 april 2024 · Basilea shareholders approve all proposals of the board of directors at the annual general meeting · Persbericht

9 april 2024 · Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics · Persbericht

4 april 2024 · Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications · Persbericht

11 maart 2024 · Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea · Persbericht

13 februari 2024 · Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio · Persbericht

19 januari 2024 · Cresemba® sales in Latin America trigger first sales milestone payment to Basilea · Persbericht

15 januari 2024 · Basilea announces acquisition of preclinical antibiotics program from Spexis · Persbericht

5 januari 2024 · Basilea provides portfolio status update · Persbericht

20 december 2023 · Basilea announces accelerated loan repayment · Persbericht

11 december 2023 · Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis · Persbericht

Mijn selecties